share_log

ETF收评 | 医药板块全天强势,医药ETF沪港深涨超3%

ETF Review | The healthcare sector remained strong throughout the day, with the csi health care etf rising more than 3% in Shanghai, Hong Kong, and Shenzhen.

Gelonghui Finance ·  Nov 12 15:33

On November 12, the three major A-share indices collectively adjusted. At the close, the Shanghai Composite Index fell by 1.39%, the Shenzhen Component Index fell by 0.65%, the chinext price index fell by 0.07%, and the Beizheng 50 Index fell by 1.98%. The total market turnover was 2587 billion yuan, an increase of 40.5 billion yuan compared to the previous day. Nearly 3800 individual stocks in the whole market were in the red. On the sector front, pharmaceutical commerce, energy metals, and traditional chinese medicine led the gains, while lithography, insurance, and military industry sectors saw the largest declines. In terms of ETFs, the pharmaceutical sector was strong throughout the day, with the China Merchants Fund's pharmaceutical ETF for Shanghai-Hong Kong-Shenzhen increasing by 3.63%, the Ping An Fund's medical innovation ETF increasing by 2.14%, and the Tianhong Fund's medical devices ETF increasing by 2.03%. The cross-border ETFs rose in the afternoon, with the Huatai-PineBridge Fund's Southeast Asia Technology ETF and the Penghua Fund's Dow Jones ETF increasing by 2.38% and 1.5% respectively, while their latest premiums were 1.73% and 1.42%. The Xinchuang sector corrected, with the Xinchuang 50 ETF and the big data industry ETF falling by 4.93% and 3.97% respectively. The military industry sector weakened, with the jungongetf and fullgoal csi military top etf falling by 4.03% and 3.99% respectively. Hong Kong stocks plummeted, with the Hong Kong Stock Connect Technology 30 ETF down by 3.88%. The financial sector remained weak, with the Hong Kong non-banking ETF down by 3.79% and the e fund csi hongkong bond investment theme etf down by 3.61%.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment